G. Steven Burrill
Welcome from the CEO
Flash required to view this video. Download the latest version here
G. Steven BurrillPodcast
![]() |
Hear G. Steven Burrill's vision of healthcare in the year 2020 in a special podcast from The Journal of Life Sciences. |
News
Biotech red hot in July as potential blockbuster M&A deals awake investors from their summer slumber August 01, 2008 | Press Release
Biotech remains upbeat in wake of market turmoil July 01, 2008 | Press Release
Genetic test industry faces tough challenges with consumers, survey finds June 17, 2008 | Press Release
See all News
Giovanni A. Ferrara
Venture PartnerPrior to joining Burrill & Company, Giovanni A. Ferrara was Manager at GeneChem Management, a healthcare venture capital firm, where he led several syndicated investments in Canada and the US. Apart from his regular investment and board responsibilities, he also held interim operating positions in portfolio companies and worked closely with BioChem Pharma’s CSO and business development team in sourcing and pursuing in-licensing opportunities, which led to two of BioChem’s largest deals, having achieved approximately $95 million in business development transactions.
Prior to joining the venture capital community, he was a financial analyst at Letko, Brosseau & Associates, a leading asset management firm. He began his career in healthcare as a pharmacist at a private cancer treatment center in Toronto focusing on experimental therapies. Mr. Ferrara completed his MBA in Finance and International Business and MSc in Physiology at McGill University, and his BSc in Biology and Genetics at the University of Toronto. He serves on the Boards of Directors of Alinea Pharmaceutical, Nanovasc, Nucleonics, CardioKine (observer), and Light Sciences Oncology (observer). He is also a member of the Advisory Board of ITI Life Sciences and a Trustee of the Molecular Sciences Institute.

.jpg)
.jpg)